Diagnosis and management of oncogenic cervical human papillomavirus infection

Infectious Disease Clinics of North America

Volumn 19, Issue 2 SPEC. ISS., 2005, Pages 439-458

  Gravitt, Patti E ^a   Jamshidi, Roxanne ^b  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b JOHNS HOPKINS BAYVIEW MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

UNCLASSIFIED DRUG; VERRUCA VACCINE; VIRUS VACCINE;

CANCER SCREENING; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; CYTOLOGY; DNA SEQUENCE; GENE MAPPING; HUMAN; IMMUNE RESPONSE; IMMUNITY; INFECTION RISK; PAPANICOLAOU TEST; REVIEW; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SEROLOGY; SEXUAL BEHAVIOR; SEXUALLY TRANSMITTED DISEASE; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; VACCINATION; VERRUCA VULGARIS; VIRUS INFECTION; WART VIRUS;

EID: 20444482878     PISSN: 08915520     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.idc.2005.03.008     Document Type: Review

References (72)

1. E.M. de Villiers Human pathogenic papillomavirus types: an update Curr Top Microbiol Immunol 186 1994 1 12
2. S.Y. Chan, H. Delius, and A.L. Halpern Analysis of genomic sequences of 95 papillomavirus types: uniting typing, phylogeny, and taxonomy J Virol 69 5 1995 3074 3083
3. N. Munoz, F. Bosch, and S. de Sanjose Epidemiologic classification of human papillomavirus types associated with cervical cancer N Engl J Med 348 6 2003 518 527
4. F. Bosch, A. Lorincz, and N. Munoz The causal relation between human papillomavirus and cervical cancer J Clin Pathol 55 2002 244 265
5. H.M. Bauer, Y. Ting, and C.E. Greer Genital human papillomavirus infection in female university students as determined by a PCR-based method JAMA 265 4 1991 472 477
6. J.M. Palefsky, E.A. Holly, and M.L. Ralston Prevalence and risk factors for anal human papillomavirus infection in human immunodeficiency virus (HIV)-positive and high-risk HIV-negative women J Infect Dis 183 3 2001 383 391
7. B.A. Weaver, Q. Feng, and K.K. Holmes Evaluation of genital sites and sampling techniques for detection of human papillomavirus DNA in men J Infect Dis 189 4 2004 677 685
8. J.M. Palefsky, S. Shiboski, and A. Moss Risk factors for anal human papillomavirus infection and anal cytologic abnormalities in HIV-positive and HIV-negative homosexual men J Acquir Immune Defic Syndr 7 6 1994 599 606
9. A.R. Kreimer, A.J. Alberg, and R. Daniel Oral human papillomavirus infection in adults is associated with sexual behavior and HIV serostatus J Infect Dis 189 4 2004 686 698
10. L.E. Manhart, and L.A. Koutsky Do condoms prevent genital HPV infection, external genital warts, or cervical neoplasia? A meta-analysis Sex Transm Dis 29 11 2002 725 735
11. K.M. Stone, K.L. Karem, and M.R. Sternberg Seroprevalence of human papillomavirus type 16 infection in the United States J Infect Dis 186 10 2002 1396 1402
12. S. Franceschi, X. Castellsague, and L. Dal Maso Prevalence and determinants of human papillomavirus genital infection in men Br J Cancer 86 5 2002 705 711
13. E.I. Svare, S.K. Kjaer, and A.M. Worm Risk factors for genital HPV DNA in men resemble those found in women: a study of male attendees at a Danish STD clinic Sex Transm Infect 78 3 2002 215 218
14. S.B. Baldwin, D.R. Wallace, and M.R. Papenfuss Human papillomavirus infection in men attending a sexually transmitted disease clinic J Infect Dis 187 7 2003 1064 1070
15. E. Lazcano-Ponce, R. Herrero, and N. Munoz High prevalence of human papillomavirus infection in Mexican males: comparative study of penile-urethral swabs and urine samples Sex Transm Dis 28 5 2001 277 280
16. X. Castellsague, F.X. Bosch, and N. Munoz Male circumcision, penile human papillomavirus infection, and cervical cancer in female partners N Engl J Med 346 15 2002 1105 1112
17. J. Palefsky, and E. Holly Immunosuppression and co-infection with HIV J Natl Cancer Inst Monogr 31 2003 41 46
18. J.A. Aberg, J.E. Gallant, and J. Anderson Primary care guidelines for the management of persons infected with human immunodeficiency virus: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America Clin Infect Dis 39 5 2004 609 629
19. J.S. Smith, C. Bosetti, and N. Munoz Chlamydia trachomatis and invasive cervical cancer: a pooled analysis of the IARC multicentric case-control study Int J Cancer 111 3 2004 431 439
20. F.X. Bosch, X. Castellsague, and N. Munoz Male sexual behavior and human papillomavirus DNA: key risk factors for cervical cancer in Spain J Natl Cancer Inst 88 15 1996 1060 1067
21. N. Munoz, F. Mendez, and H. Posso Incidence, duration, and determinants of cervical human papillomavirus infection in a cohort of Colombian women with normal cytological results J Infect Dis 190 12 2004 2077 2087
22. M. Molano, H. Posso, and E. Weiderpass Prevalence and determinants of HPV infection among Colombian women with normal cytology Br J Cancer 87 3 2002 324 333
23. R. Herrero, A. Hildesheim, and C. Bratti Population-based study of human papillomavirus infection and cervical neoplasia in rural Costa Rica J Natl Cancer Inst 92 6 2000 464 474
24. E. Lazcano-Ponce, R. Herrero, and N. Munoz Epidemiology of HPV infection among Mexican women with normal cervical cytology Int J Cancer 91 3 2001 412 420
25. G.Y. Ho, R. Bierman, and L. Beardsley Natural history of cervicovaginal papillomavirus infection in young women N Engl J Med 338 7 1998 423 428
26. D.R. Brown, M.L. Shew, and B. Qadadri A longitudinal study of genital human papillomavirus infection in a cohort of closely followed adolescent women J Infect Dis 191 2 2005 182 192
27. E.L. Franco, L.L. Villa, and J.P. Sobrinho Epidemiology of acquisition and clearance of cervical human papillomavirus infection in women from a high-risk area for cervical cancer J Infect Dis 180 5 1999 1415 1423
28. R.W. Tindle Immune evasion in human papillomavirus-associated cervical cancer Nat Rev Cancer 2 1 2002 59 65
29. M.A. Stanley Immunobiology of papillomavirus infections J Reprod Immunol 52 1-2 2001 45 59
30. J.J. Carter, L.A. Koutsky, and J.P. Hughes Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection J Infect Dis 181 6 2000 1911 1919
31. R.P. Viscidi, M. Schiffman, and A. Hildesheim Seroreactivity to human papillomavirus (HPV) types 16, 18, or 31 and risk of subsequent HPV infection: results from a population-based study in Costa Rica Cancer Epidemiol Biomarkers Prev 13 2 2004 324 327
32. R. Viscidi, B. Snyder, and S. Cu-Uvin Human papillomavirus capsid antibody response to natural infection and risk of subsequent HPV infection in HIV-positive and HIV-negative women Cancer Epidemiol Biomarkers Prev 14 1 2005 283 288
33. L.A. Koutsky, K.A. Ault, and C.M. Wheeler A controlled trial of a human papillomavirus type 16 vaccine N Engl J Med 347 21 2002 1645 1651
34. D.M. Harper, E.L. Franco, and C. Wheeler Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial Lancet 364 9447 2004 1757 1765
35. J.M. Palefsky, H. Minkoff, and L.A. Kalish Cervicovaginal human papillomavirus infection in human immunodeficiency virus-1 (HIV)-positive and high-risk HIV-negative women J Natl Cancer Inst 91 3 1999 226 236
36. L. Ahdieh, R. Klein, and R.D. Burk Prevalence, incidence and type-specific persistence of human papillomavirus in human immunodeficiency virus (HIV)-positive and HIV-negative women J Infect Dis 184 6 2001 682 690
37. M. Frisch, R. Biggar, and E. Engels AIDS-Cancer match registry study group. Association of cancer with AIDS-related immunosuppression in adults JAMA 285 13 2001 1736 1745
38. C.B. Woodman, S. Collins, and H. Winter Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study Lancet 357 9271 2001 1831 1836
39. R.L. Winer, N.B. Kiviat, and J.P. Hughes Development and duration of human papillomavirus lesions, after initial infection J Infect Dis 191 5 2005 731 738
40. S.K. Kjaer, A.J. van den Brule, and G. Paull Type specific persistence of high risk human papillomavirus (HPV) as indicator of high grade cervical squamous intraepithelial lesions in young women: population based prospective follow up study BMJ 325 7364 2002 572
41. N.F. Schlecht, S. Kulaga, and J. Robitaille Persistent human papillomavirus infection as a predictor of cervical intraepithelial neoplasia JAMA 286 24 2001 3106 3114
42. N. Ylitalo, A. Josefsson, and M. Melbye A prospective study showing long-term infection with human papillomavirus 16 before the development of cervical carcinoma in situ Cancer Res 60 21 2000 6027 6032
43. R. Alvarez, M. Conner, and H. Weiss The efficacy of 9-cis-retinoic acid (aliretinoin) as a chemopreventive agent for cervical dysplasia: results of a randomized double-blind clinical trial Cancer Epidemiol Biomarkers Prev 12 2 2003 114 119
44. M. Follen, E.N. Atkinson, and D. Schottenfeld A randomized clinical trial of 4-hydroxyphenylretinamide for high-grade squamous intraepithelial lesions of the cervix Clin Cancer Res 7 11 2001 3356 3365
45. N. Munoz, S. Franceschi, and C. Bosetti Role of parity and human papillomavirus in cervical cancer: the IARC multicentric case-control study Lancet 359 9312 2002 1093 1101
46. X. Castellsague, and N. Munoz Cofactors in human papillomavirus carcinogenesis - role of parity, oral contraceptives, and tobacco smoking J Natl Cancer Inst Monogr 31 2003 20 28
47. M. Plummer, R. Herrero, and S. Franceschi Smoking and cervical cancer: pooled analysis of the IARC multi-centric case-control study Cancer Causes Control 14 9 2003 805 814
48. P.E. Castle, S. Wacholder, and A.T. Lorincz A prospective study of high-grade cervical neoplasia risk among human papillomavirus-infected women J Natl Cancer Inst 94 18 2002 1406 1414
49. V. Moreno, F.X. Bosch, and N. Munoz Effect of oral contraceptives on risk of cervical cancer in women with human papillomavirus infection: the IARC multicentric case-control study Lancet 359 9312 2002 1085 1092
50. J. Green, A. Berrington de Gonzalez, and J.S. Smith Human papillomavirus infection and use of oral contraceptives Br J Cancer 88 11 2003 1713 1720
51. S. Shapiro, L. Rosenberg, and M. Hoffman Risk of invasive cancer of the cervix in relation to the use of injectable progestogen contraceptives and combined estrogen/progestogen oral contraceptives (South Africa) Cancer Causes Control 14 5 2003 485 495
52. J.S. Smith, J. Green, and A. Berrington de Gonzalez Cervical cancer and use of hormonal contraceptives: a systematic review Lancet 361 9364 2003 1159 1167
53. J.S. Smith, R. Herrero, and C. Bosetti Herpes simplex virus-2 as a human papillomavirus cofactor in the etiology of invasive cervical cancer J Natl Cancer Inst 94 21 2002 1604 1613
54. D. Tran-Thanh, D. Provencher, and A. Koushik Herpes simplex virus type II is not a cofactor to human papillomavirus in cancer of the uterine cervix Am J Obstet Gynecol 188 1 2003 129 134
55. M. Lehtinen, P. Koskela, and E. Jellum Herpes simplex virus and risk of cervical cancer: a longitudinal, nested case-control study in the Nordic countries Am J Epidemiol 156 8 2002 687 692
56. K.L. Wallin, F. Wiklund, and T. Luostarinen A population-based prospective study of Chlamydia trachomatis infection and cervical carcinoma Int J Cancer 101 4 2002 371 374
57. P.E. Castle, S.L. Hillier, and L.K. Rabe An association of cervical inflammation with high-grade cervical neoplasia in women infected with oncogenic human papillomavirus (HPV) Cancer Epidemiol Biomarkers Prev 10 10 2001 1021 1027
58. Y.C. Yang, C.L. Chang, and Y.W. Huang Possible cofactor in cervical carcinogenesis: proliferation index of the transformation zone in cervicitis Chang Gung Med J 24 10 2001 615 620
59. J. Peto, C. Gilham, and O. Fletcher The cervical cancer epidemic that screening has prevented in the UK Lancet 364 9430 2004 249 256
60. D. Saslow, C.D. Runowicz, and D. Solomon American Cancer Society guideline for the early detection of cervical neoplasia and cancer CA Cancer J Clin 52 6 2002 342 362
61. J.T. Cox The clinician's view: role of human papillomavirus testing in the American Society for Colposcopy and Cervical Pathology Guidelines for the management of abnormal cervical cytology and cervical cancer precursors Arch Pathol Lab Med 127 8 2003 950 958
62. Screening for cervical cancer: recommendations and rationale. Available at: http://www.ahrq.gov/clinic/3rduspstf/cervcan/cervcanrr.pdf. Accessed January 15, 2003.
63. D. Solomon, D. Davey, and R. Kurman The 2001 Bethesda System: terminology for reporting results of cervical cytology JAMA 287 16 2002 2114 2119
64. D.D. Davey, R.M. Austin, and G. Birdsong ASCCP patient management guidelines: Pap test specimen adequacy and quality indicators Am J Clin Pathol 118 5 2002 714 718
65. C.L. Peyton, M. Schiffman, and A.T. Lorincz Comparison of PCR- and hybrid capture-based human papillomavirus detection systems using multiple cervical specimen collection strategies J Clin Microbiol 36 11 1998 3248 3254
66. ALTS. A randomized trial on the management of low-grade squamous intraepithelial lesion cytology interpretations Am J Obstet Gynecol 188 6 2003 1393 1400
67. ALTS. Results of a randomized trial on the management of cytology interpretations of atypical squamous cells of undetermined significance Am J Obstet Gynecol 188 6 2003 1383 1392
68. A.B. Moscicki, S. Shiboski, and N.K. Hills Regression of low-grade squamous intra-epithelial lesions in young women Lancet 364 9446 2004 1678 1683
69. J.J. Kim, T.C. Wright, and S.J. Goldie Cost-effectiveness of alternative triage strategies for atypical squamous cells of undetermined significance JAMA 287 18 2002 2382 2390
70. E.L. Franco Primary screening of cervical cancer with human papillomavirus tests J Natl Cancer Inst Monogr 31 2003 89 96
71. J. Cuzick, A. Szarewski, and H. Cubie Management of women who test positive for high-risk types of human papillomavirus: the HART study Lancet 362 9399 2003 1871 1876
72. P. Gravitt, and K. Shah A virus-based vaccine may prevent cervical cancer Curr Infect Dis Rep 7 2005 125 131